The Therapeutic Role of Xenobiotic Nuclear Receptors Against Metabolic Syndrome.


Journal

Current drug metabolism
ISSN: 1875-5453
Titre abrégé: Curr Drug Metab
Pays: Netherlands
ID NLM: 100960533

Informations de publication

Date de publication:
2019
Historique:
received: 14 03 2018
revised: 05 04 2018
accepted: 29 05 2018
pubmed: 12 6 2018
medline: 25 7 2019
entrez: 12 6 2018
Statut: ppublish

Résumé

Diabetes, with an increased prevalence and various progressive complications, has become a significant global health challenge. The concrete mechanisms responsible for the development of diabetes still remain incompletely unknown, although substantial researches have been conducted to search for the effective therapeutic targets. This review aims to reveal the novel roles of Xenobiotic Nuclear Receptors (XNRs), including the Peroxisome Proliferator-Activated Receptor (PPAR), the Farnesoid X Receptor (FXR), the Liver X Receptor (LXR), the Pregnane X Receptor (PXR) and the Constitutive Androstane Receptor (CAR), in the development of diabetes and provide potential strategies for research and treatment of metabolic diseases. We retrieved a large number of original data about these five XNRs and organized to focus on their recently discovered functions in diabetes and its complications. Increasing evidences have suggested that PPAR, FXR, LXR ,PXR and CAR are involved in the development of diabetes and its complications through different mechanisms, including the regulation of glucose and lipid metabolism, insulin and inflammation response and related others. PPAR, FXR, LXR, PXR, and CAR, as the receptors for numerous natural or synthetic compounds, may be the most effective therapeutic targets in the treatment of metabolic diseases.

Sections du résumé

BACKGROUND BACKGROUND
Diabetes, with an increased prevalence and various progressive complications, has become a significant global health challenge. The concrete mechanisms responsible for the development of diabetes still remain incompletely unknown, although substantial researches have been conducted to search for the effective therapeutic targets. This review aims to reveal the novel roles of Xenobiotic Nuclear Receptors (XNRs), including the Peroxisome Proliferator-Activated Receptor (PPAR), the Farnesoid X Receptor (FXR), the Liver X Receptor (LXR), the Pregnane X Receptor (PXR) and the Constitutive Androstane Receptor (CAR), in the development of diabetes and provide potential strategies for research and treatment of metabolic diseases.
METHODS METHODS
We retrieved a large number of original data about these five XNRs and organized to focus on their recently discovered functions in diabetes and its complications.
RESULTS RESULTS
Increasing evidences have suggested that PPAR, FXR, LXR ,PXR and CAR are involved in the development of diabetes and its complications through different mechanisms, including the regulation of glucose and lipid metabolism, insulin and inflammation response and related others.
CONCLUSION CONCLUSIONS
PPAR, FXR, LXR, PXR, and CAR, as the receptors for numerous natural or synthetic compounds, may be the most effective therapeutic targets in the treatment of metabolic diseases.

Identifiants

pubmed: 29886826
pii: CDM-EPUB-91023
doi: 10.2174/1389200219666180611083155
doi:

Substances chimiques

Constitutive Androstane Receptor 0
Liver X Receptors 0
Peroxisome Proliferator-Activated Receptors 0
Pregnane X Receptor 0
Receptors, Cytoplasmic and Nuclear 0
Xenobiotics 0
farnesoid X-activated receptor 0C5V0MRU6P

Types de publication

Journal Article Review

Langues

eng

Pagination

15-22

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Shuqi Pu (S)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Xiaojie Wu (X)

Department of Immunology, Binzhou Medical University, Yantai, China.

Xiaoying Yang (X)

Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology and Laboratory of Infection and Immunity, Xuzhou Medical University, Xuzhou, China.

Yunzhan Zhang (Y)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Yunkai Dai (Y)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Yueling Zhang (Y)

Department of Operating Theatre, Binzhou People's Hospital, Binzhou, China.

Xiaoting Wu (X)

Department of Operating Theatre, Binzhou People's Hospital, Binzhou, China.

Yan Liu (Y)

Department of Immunology, Binzhou Medical University, Yantai, China.

Xiaona Cui (X)

Jiangsu Key Laboratory of Brain Disease Bioinformation, Research Center for Biochemistry and Molecular Biology, Xuzhou Medical University, Xuzhou, China.

Haiyong Jin (H)

Department of Otolaryngology, the Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.

Jianhong Cao (J)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Ruliu Li (R)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Jiazhong Cai (J)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Qizhi Cao (Q)

Department of Immunology, Binzhou Medical University, Yantai, China.

Ling Hu (L)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Yong Gao (Y)

PI-WEI Institute, Guangzhou University of Chinese Medicine, Guangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH